发布求助
文献互助 智能选刊 最新文献

Idrugs最新文献

筛选
英文 中文
American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 1. 美国糖尿病协会-第70届科学会议-新疗法的研究:第1部分。
Idrugs Pub Date : 2010-09-01
Gary Croasdell
{"title":"American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 1.","authors":"Gary Croasdell","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucagon-like peptide-1 (GLP-1) agonist taspoglutide (Roche Holding AG/Teijin Ltd/ Chugai Pharmaceutical Co Ltd), the GLP-1 analog SKL-18287 (Sanwa Kagaku Kenkyusho Co Ltd), the sodium glucose transporter-2 (SGLT2) inhibitor ASP-1941 (Astellas Pharma Inc/Kotobuki Pharmaceutical Co Ltd), the dual SGLT2/1 inhibitor LX-4211 (Lexicon Pharmaceuticals Inc), and the selective PPARgamma modulator INT-131 (InteKrin Therapeutics Inc).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"595-7"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29267587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2. 美国糖尿病协会-第70届科学会议-新疗法的研究:第2部分。
Idrugs Pub Date : 2010-09-01
Gary Croasdell
{"title":"American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2.","authors":"Gary Croasdell","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The American Diabetes Association 70th Scientific Sessions, held in Orlando, FL, USA, included topics covering new therapeutic developments in the field of diabetes research. This conference report highlights selected presentations on new research with novel agents. Investigational drugs discussed include the glucokinase activator SKL-19014 (Sanwa Kagaku Kenkyusho Co Ltd), the GPR119 agonist AS-1535907 (Astellas Pharma Inc), the apical sodium-dependent bile transporter (ASBT) inhibitor SC-435 (Satiogen Pharmaceuticals Inc), the VEGF-A activator SB-509 (Sangamo BioSciences Inc), and the protein tyrosine phosphatase 1b (PTP-1b) antisense inhibitor ISIS-113715 (ISIS Pharmaceuticals Inc).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"598-600"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29267588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ADMET--Fifth Annual SMi Conference. ADMET——第五届SMi年会。
Idrugs Pub Date : 2010-09-01
John E Comer
{"title":"ADMET--Fifth Annual SMi Conference.","authors":"John E Comer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>SMi's fifth annual ADMET Conference, held in London, included topics covering new developments in the field of ADMET. This conference report highlights selected presentations on ADME optimization in drug discovery; targeting drugs to the brain; predicting bonds that might be attacked during metabolism; treating Caco-2 membranes with vinblastine to enhance P-glycoprotein interactions; predictive ADMET in hit-to-lead optimization; structure-based studies of ADMET targets; an accelerated process for integrated drug development; building hypotheses in lead selection and optimization; supersaturation effects; the prediction of drug-drug interactions; developing a mechanism-based pharmacokinetic/pharmacodynamic model; drug transporter assays in drug discovery; time-dependent inhibition screens in early drug discovery; the system-dependent inhibition of CYP enzymes; the integrating predictive toxicology framework OpenTox; high-content analysis for predictive cytotoxicity testing; and emerging in vitro toxicity assays.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"610-4"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29269510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
API Global Sourcing Strategies 2010. API全球采购策略2010。
Idrugs Pub Date : 2010-09-01
Shannon Bennett
{"title":"API Global Sourcing Strategies 2010.","authors":"Shannon Bennett","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The API Global Sourcing Strategies 2010 Conference, held in Berlin, included topics covering new developments in the field of global sourcing of active pharmaceutical ingredients (APIs). This conference report highlights selected presentations on development in Eastern API markets, specifically India and China, factors influencing changes in global API sourcing, and risk mitigation in API sourcing.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"605-6"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29269508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The American Society for Virology--29th Annual Meeting. 美国病毒学学会第29届年会。
Idrugs Pub Date : 2010-09-01
Jennifer Minieri Arroyo
{"title":"The American Society for Virology--29th Annual Meeting.","authors":"Jennifer Minieri Arroyo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The American Society for Virology 29th Annual Meeting, held in Bozeman, MT, USA, included topics covering new vaccine technologies, delivery methods and treatments in the field of virology. This conference report highlights selected presentations on human norovirus (HuNoV), SARS coronavirus and Rift Valley fever virus vaccine technologies; programmed cell death-1 (PD1) blockade and HyperAcute alpha-Gal platform technology methods; aerosol vaccination delivery; novel technologies to produce influenza virus-like particles (VLP) in mammalian cell lines; and investigational human rotavirus vaccines.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"615-8"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29269511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles. 利用靶向和稳定的纳米颗粒克服白细胞中的RNAi转导。
Idrugs Pub Date : 2010-09-01
Rofa Elfakess, Dan Peer
{"title":"Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles.","authors":"Rofa Elfakess,&nbsp;Dan Peer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>RNAi-based approaches have contributed significantly to the improved understanding of gene expression and function in vitro. The ability to apply these strategies in vivo to validate the role of specific genes in normal or pathological conditions, and to induce gene silencing, has led to new possibilities for using RNAi as a novel therapeutic modality. However, the translation of RNAi from an effective genomic tool into clinical applications has been hindered by the challenge of delivering RNAi molecules to their target tissues by systemic administration, particularly to hematopoietic cells. This feature review describes the current systemic RNAi delivery platforms targeted to leukocytes, with a focus on the integrin-targeted stabilized nanoparticles strategy, which uses leukocyte integrins for the delivery of siRNAs exclusively to cells of the immune system.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"626-31"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29267467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. Tivozanib，一种泛vegfr酪氨酸激酶抑制剂，用于实体瘤的潜在治疗。
Idrugs Pub Date : 2010-09-01
Antonella De Luca, Nicola Normanno
{"title":"Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.","authors":"Antonella De Luca,&nbsp;Nicola Normanno","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tivozanib (AV-951; KRN-951), being developed by AVEO Pharmaceuticals Inc and Kyowa Hakko Kirin Co Ltd, is an orally active, ATP-competitive, small-molecule, quinoline-urea derivative that inhibits VEGFR tyrosine kinase for the potential treatment of cancer. In particular, tivozanib is able to markedly inhibit the ligand-induced phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3 at picomolar concentrations. In preclinical studies, tivozanib produced a significant inhibition of tumor growth and angiogenesis in several different xenograft tumor models in athymic rats. In a phase I clinical trial, tivozanib was safe and tolerable when administered at oral doses up to 1.5 mg on a schedule of 4 weeks on, 2 weeks off treatment. Results from a phase II clinical trial in patients with advanced renal cell carcinoma reported an overall response rate of 25.4% and a median progression-free survival of 11.8 months in patients treated with tivozanib as a single agent. Hypertension and dysphonia were the most frequent adverse events. At the time of publication, a phase III clinical trial was recruiting patients with advanced renal cancer to assess tivozanib in comparison with sorafenib. Clinical trials are currently ongoing to evaluate the safety and antitumor activity of tivozanib in breast, lung and colorectal cancer. Tivozanib might represent a promising anticancer agent in several different tumor types.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"636-45"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29267469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asthma & COPD--IQPC's Second Conference. 哮喘和慢性阻塞性肺病——IQPC第二次会议。
Idrugs Pub Date : 2010-09-01
Matthew C Catley
{"title":"Asthma & COPD--IQPC's Second Conference.","authors":"Matthew C Catley","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The International Quality & Productivity Center's (IQPC) Second Asthma & COPD conference, held in Philadelphia, included topics covering new therapeutic developments in the field of asthma and COPD. This conference report highlights selected presentations on mAb treatments for asthma, including targeting IL-5, IL-13, IL-9 and TNFa, CCR3 inhibitors, histamine H4 receptor inhibition, novel mouse models of COPD and inhaled antisense asthma therapies. Investigational drugs discussed include mepolizumab (GlaxoSmithKline plc), benralizumab (BioWa Inc/Kyowa Hakko Kirin Co Ltd/MedImmune LLC), AMG-317 (Amgen Inc/Takeda Bio Development Center Ltd), TPI-ASM-8 (Pharmaxis Ltd) and AIR-645 (Altair Therapeutics Inc).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"601-4"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29269507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Society for Eye Research--XIXth Biennial Meeting. 国际眼科研究学会第19届双年会议。
Idrugs Pub Date : 2010-09-01
Ulrich Pfeffer
{"title":"International Society for Eye Research--XIXth Biennial Meeting.","authors":"Ulrich Pfeffer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The International Society for Eye Research--XIXth Biennial Meeting, held in Montreal, included topics covering new therapeutic developments in the field of eye disease research, including ocular oncology. This conference report highlights selected presentations on uveal melanoma and retinoblastoma.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 9","pages":"619-21"},"PeriodicalIF":0.0,"publicationDate":"2010-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29269512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor. 治疗性蛋白的配方和免疫原性:产品质量是关键因素。
Idrugs Pub Date : 2010-08-01
Joel Richard, Nadia Prang
{"title":"The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.","authors":"Joel Richard,&nbsp;Nadia Prang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The formation of anti-drug antibodies represents a risk that should be assessed carefully during biopharmaceutical drug product (DP) development, as such antibodies compromise safety and efficacy and may alter the pharmacokinetic properties of a compound. This feature review discusses immunogenicity issues in biopharmaceutical DP development, with a focus on product quality. Excipient-induced and aggregate-induced immunogenicity are reviewed based on the concepts of 'aggregation-competent' species and 'provocative' aggregates. In addition, the influence of formulation parameters, such as particulates and contaminants appearing in the DP during processing and storage, on aggregate-induced immunogenicity are presented, including the role of fill-and-finish equipments and the effect of interactions with container materials. Furthermore, methods to detect and quantify aggregation and precursor conformational changes in a protein formulation are reviewed, and immunological mechanisms that may lead to aggregate-induced immunogenicity are proposed and discussed.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 8","pages":"550-8"},"PeriodicalIF":0.0,"publicationDate":"2010-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29197912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信